Celebrating 20 Years of IP Excellence

Image accompanying blogpost on "Cancerous Battle: Novartis and NATCO clash over Eltrombopag"

Cancerous Battle: Novartis and NATCO clash over Eltrombopag

In a landmark decision, the Delhi High Court overturned an injunction against Natco, allowing them to produce a generic version of Novartis’s cancer drug. The Court held that Novartis’s patent on a specific salt form of the drug (ELT-O) lacked novelty due to its coverage in an earlier patent (IN’176). Continue Reading Cancerous Battle: Novartis and NATCO clash over Eltrombopag

Read more

Drug Discovery

Drug Discovery

Nature of Company: Drug Discovery Why they approached us: Did not have an IP Management Process. Did not have an in house IP team to manage IP and IP related transactions. Needed cost effective worldwide patent services. What did we do: IP Audit was performed to understand the R and D Process and set up a robust IP system within the organization. Organized IP training program across the company to build IP awareness. Worked…

Read more